Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vifor

- PMLiVE

Researchers identify early treatment strategy for diabetic patients at risk of kidney disease

The chronic disease is currently the leading cause of kidney failure in the UK

- PMLiVE

Novo Nordisk shares promising phase 3 data for semaglutide in diabetes and chronic kidney disease

An estimated 40% of people living with type 1 or type 2 diabetes will develop CKD in their lifetime

- PMLiVE

CHMP recommends Travere and CSL Vifor’s Filspari to treat rare kidney disease IgAN

The rare form of kidney disease is estimated to affect around 25 per million adults worldwide

- PMLiVE

NICE recommends STADA and Calliditas’ Kinpeygo to treat rare kidney disease IgAN

Affecting approximately 14,000 in England, IgA nephropathy occurs when IgA accumulates in the kidneys, causing inflammation and scarring

- PMLiVE

Novartis shares positive phase 3 results for atrasentan in rare kidney disease

The company gained access to the candidate after it acquired Chinook Therapeutics

- PMLiVE

It’s the Era of Outcomes at ERA 2023

The Medscape team has bid farewell to the beautiful city of Milano, Italy and our European nephrology colleagues. The team was thrilled to meet up with so many ground-breaking clinicians,...

Medscape Education Global

International NASH Day 2023

Shari Dermer, PhD of Medscape Education, hosted Michael Betel, Founder and President of Fatty Liver Alliance, in an engaging conversation around the importance of NASH awareness, diagnosis, and prognosis. Listen...

Medscape Education Global

- PMLiVE

Elevating Nephrology Outcomes at #ERA23

Medscape is headed back to Milano, Italy for the 2023 European Renal Association conference, #ERA23.This year, the team is elevating the outcomes of recent nephrology education programs to share the story...

Medscape Education Global

- PMLiVE

Novartis to acquire Chinook Therapeutics for approximately $3.5bn

The deal marks a notable expansion to the Swiss drugmaker's kidney disease pipeline

- PMLiVE

New research shows potential to treat kidney disease with common medicines

Acute kidney injuries cause around 20% of all emergency hospital admissions in the UK

- PMLiVE

FDA advisory committee recommends Ardelyx’s Xphozah for chronic kidney disease

The phase 3 trials supporting the submission met all primary and key secondary endpoints

- PMLiVE

Merck’s Prevymis shows promise in phase 3 cytomegalovirus disease prevention trial

The drug demonstrated non-inferior efficacy compared to standard of care valganciclovir

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links